MediWound’s CEO and Chairman Increase Their Holdings as a Pivotal Trial Milestone Nears (NASDAQ: MDWD)

Summary by AI BETAClose X

Three senior MediWound executives paid a combined $418,237 to exercise 31,038 warrants at $13.475 per share (expiring Nov 28), with the chairman buying 16,336 shares for ~$220,128, the CEO 8,168 for ~$110,064 and a director 6,534 for ~$88,046; commercial traction includes Vericel-reported NexoBrid revenue of $2.3 million in Q3 (up 54% YoY, 46% QoQ) plus $3.0 million federal procurement for $5.3 million total and orders from >80 burn centers (~70 repeat buyers); EscharEx Phase 3 VALUE targets 216 patients across ~40 sites with enrollment and an interim sample-size reassessment expected by end Q1 2027 and an independent DSMB recommending continuation.

Disclaimer*

UK 100

Latest directors dealings